Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Reliability of Reliability Adjustment for Quality Improvement and Value-based Payment
Wakeam, Elliot, Hyder, Joseph A.

Anesthesiology | September 10, 2015 | Volume: 124 | Issue: 1 | Pages: 16-18

10.1097/aln.0000000000000845 | PMID 26352379 Get It

Palmar-plantar erythrodysesthesia
Khanna, Sahil , Gupta, Arjun , Mehta, Anurag

BMJ Case Reports | September 10, 2015 | Volume: 2015 | Issue: No issue available | Pages: bcr2015212434

10.1136/bcr-2015-212434 | PMID 26359464 Get It

Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study
Feng, Tom , Sun, Xizi, Howard, Lauren E. , Vidal, Adriana C. , Gaines, Alexis R., Moreira, Daniel M. , Castro‐Santamaria, Ramiro , Andriole, Gerald L. , Freedland, Stephen J. , Howard, Lauren E

Cancer Prevention Research | September 10, 2015 | Volume: 8 | Issue: 11 | Pages: 1055-1060

10.1158/1940-6207.capr-15-0141 | PMID 26353947 Get It

Abstract The role of metformin in prostate cancer chemoprevention remains unclear. REDUCE, which followed biopsy-negative men with protocol-dictated PSA-independent biopsies at 2- and 4-years, provides an opportunity to evaluate the link between metformin use and prostate cancer diagnosis with minimal confounding from screening biases. In diabetic men from REDUCE, we tested the association between metformin use, use of other antidiabetic medications, versus no antidiabetic medication use, and prostate cancer diagnosis as well as prostate cancer grade (low-grade Gleason 4–6 and high-grade Gleason 7–10) using logistic regression. Of the 540 diabetic men with complete data, 205 (38%) did not report use of any antidiabetic medications, 141 (26%) reported use of at least one antidiabetic medication other than metformin, and 194 (36%) reported use of metformin. During the 4-year study, 122 men (23%) were diagnosed with prostate cancer. After adjusting for various clinical and demographic characteristics, we found that metformin use was not significantly associated with total (OR, 1.19; P = 0.50), low- (OR, 1.01; P = 0.96), or high-grade (OR, 1.83; P = 0.19) prostate cancer diagnosis. Likewise, there was no significant association between the use of non-metformin antidiabetic medications and prostate cancer risk in both crude (OR, 1.02; P = 0.95) and multivariable analysis (OR, 0.85; P = 0.56). Furthermore, the interactions between antidiabetic medication use and BMI, geographic location, coronary artery disease, smoking, and treatment group were not significant (all P > 0.05). Among diabetic men with a negative prestudy biopsy who all underwent biopsies largely independent of PSA, metformin use was not associated with reduced risk of prostate cancer diagnosis. Cancer Prev Res; 8(11); 1055–60. ©2015 AACR.
The Metastatic Spine Disease Multidisciplinary Working Group Algorithms
Robinson, Clifford G. , Meyer, Jeffrey , Gangi, Afshin , Callstrom, Matthew R. , Chao, Samuel T. , Tine, Brian Andrew Van, Bruel, Brian M., Long, Jeremiah R. , Timmerman, Robert , Buchowski, Jacob M. , Jennings, Jack W. , Wallace, Adam N, Tran, Nam D, Van Tine, Brian A, Long, Jeremiah, Timmerman, Robert D, Wallace, Adam N. , Tran, Nam , Morris, Jonathan M. , Robinson, Clifford

The Oncologist | September 10, 2015 | Volume: 20 | Issue: 10 | Pages: 1205-1215

10.1634/theoncologist.2015-0085 | PMID 26354526 Get It

AbstractThe Metastatic Spine Disease Multidisciplinary Working Group consists of medical and radiation oncologists, surgeons, and interventional radiologists from multiple comprehensive cancer centers who have developed evidence- and expert opinion-based algorithms for managing metastatic spine disease. The purpose of these algorithms is to facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding the use of available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation. This consensus document details the evidence supporting the Working Group algorithms and includes illustrative cases to demonstrate how the algorithms may be applied.Implications for Practice:The Metastatic Spine Disease Multidisciplinary Working Group algorithms can facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation.
Procedural Headache Medicine in Neurology Residency Training: A Survey of US Program Directors
Robertson, Carrie E. , Levin, Morris , Friedman, Deborah I. , Robbins, Matthew S. , Ailani, Jessica , Dodick, David W. , Robertson, Carrie E , Friedman, Deborah I

Headache: The Journal of Head and Face Pain | September 9, 2015 | Volume: 56 | Issue: 1 | Pages: 79-85

10.1111/head.12695 | PMID 26352267 Get It

Objective To survey neurology residency program directors (PDs) on trainee exposure, supervision, and credentialing in procedures widely utilized in headache medicine. Background Clinic‐based procedures have assumed a prominent role in headache therapy. Headache fellows obtain procedural competence, but reliance on fellowship‐trained neurologists cannot match the population eligible for treatments. The inclusion of educational modules and mechanisms for credentialing trainees pursuing procedural competence in residency curricula at individual programs is not known. Methods A web‐based survey of US neurology residency PDs was designed by the American Headache Society (AHS) procedural special interest section in collaboration with AHS and American Academy of Neurology's Headache and Facial Pain section leadership. The survey addressed exposure, training, and credentialing in: (1) onabotulinumtoxinA (onabotA) injections, (2) extracranial peripheral nerve blocks (PNBs), and (3) trigger point injections (TPIs). Results Fifty‐five PDs (42.6%) completed the survey. Compared to noncompleters, survey completers were more likely to feature headache fellowships at their institutions (38.2% vs 10.8%, P =0.0002). High exposure (onabotA=90.9%, PNBs=80.0%, TPIs=70.9%) usually featured hands‐on patient instruction (66.2%) and lectures (55.7%). Supervised performance rates were high (onabotA=65.5%, PNBs=60.0%, TPIs=52.7%), usually in continuity clinic (60.0%) or headache elective (50.9%). Headache specialists (69.1%) or general neurology (32.7%) faculty most commonly trained residents. Formal credentialing was uncommon (16.4‐18.2%), mostly by documenting supervised procedures (25.5%). Only 27.3% of programs permitted trainees to perform procedures independently. Most PDs felt procedural exposure (80.0‐90.9%) and competence (50.9‐56.4%) by all trainees was important. Conclusions Resident exposure to procedures for headache is high, but credentialing mechanisms, while desired by most PDs, are not generally in place. Implementation of a credentialing process may ensure trainees enter practice with the ability to perform procedures safely and effectively.
It takes three to tango
Dronca, Roxana

Science Translational Medicine | September 9, 2015 | Volume: 7 | Issue: 304 | Pages: No page available

10.1126/scitranslmed.aad3067 Get It

Prolonged inhibition of three HER/EGFR subtypes results in regression of HER2-amplified gastrointestinal carcinomas.
Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta‐analysis
Njei, Basile , Ewelukwa, Oforbuike, Ditah, Ivo, Foma, Munoh K., Lim, Joseph K. , Gupta, Neil

Liver International | September 9, 2015 | Volume: 36 | Issue: 5 | Pages: 634-641

10.1111/liv.12959 | PMID 26352650 Get It

AbstractBackground & AimsAntiviral drugs are safe and effective in the third trimester to prevent intrauterine transmission of hepatitis B virus, and are recommended for hepatitis B virus (HBV) infected gravid mothers (between weeks 28 and 32) with high viral load, followed by postnatal hepatitis B immunization in the newborn. We estimated the comparative efficacy of antiviral drugs for prevention of vertical transmission of HBV, through a network meta‐analysis of clinical trials.MethodsWe conducted a comprehensive search of MEDLINE, EMBASE and published proceedings from major liver meetings from January 1980 to November 2014. We conducted pair‐wise meta‐analyses and Bayesian framework using Markov chain Monte Carlo methods, combining direct and indirect evidence for any given pair of treatments.ResultsSeventeen clinical trials involving 2764 newborns of hepatitis B surface antigen seropositive mothers were eligible for analysis. There were no clinical trials involving tenofovir or entecavir. On pair‐wise meta‐analyses, telbivudine (hazard ratio, HR 0.12, 95% confidence interval (CI) 0.04–0.37; I2 = 0%), and Lamivudine (HR 0.40, 95% CI 0.24–0.65; I2 = 0%), were more effective than placebo in reducing vertical transmission of HBV in high viremic hepatitis B e antigen (HBeAg)‐positive chronic Hepatitis B Chinese patients. Sensitivity analyses limited to studies with HBeAg seropositive mothers revealed similar results.ConclusionsBased on a Bayesian network meta‐analysis of clinical trials, combining direct and indirect treatment comparisons, telbivudine appears to be more effective than Lamivudine for preventing vertical transmission of HBV infection. Trials assessing the efficacy of tenofovir or entecavir compared to placebo or other antiviral drugs are lacking.
Persistent Notochord in a Fetus with COL2A1 Mutation
Codsi, Elisabeth , Brost, Brian , Faksh, Arij , Volk, Amber K., Borowski, Kristi, Borowski, Kristi S

Case Reports in Obstetrics and Gynecology | September 9, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-3

10.1155/2015/935204 | PMID 26435866 Get It

Multiple anomalies including micromelia, poor mineralization of the vertebrae, and a persistent notochord were identified on second trimester ultrasound in a fetus with aCOL2A1mutation. To our knowledge, this represents the first case of a persistent notochord associated with aCOL2A1mutation in humans. In this case report, we describe ultrasound and postmortem findings and review the pathogenesis associated with a persistent notochord.
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, Robert A. , Fuleihan, Ghada El‐Hajj , Bauer, Douglas C. , Camacho, Pauline M., Clines, Gregory A. , Edwards, Beatrice J. , Favus, Murray J., Greenspan, Susan L., McKinney, Ross E. , Pignolo, Robert J. , Sellmeyer, Deborah E. , Clarke, Bart L, Drake, Matthew T. , Clarke, B.L. , Compston, Juliet , Bauer, Douglas C , El-Hajj Fuleihan, Ghada

Journal of Bone and Mineral Research | September 9, 2015 | Volume: 31 | Issue: 1 | Pages: 16-35

10.1002/jbmr.2708 | PMID 26350171 Get It

ABSTRACT Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip T-score, between –2 and –2.5 in FLEX and below –2.5 in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip T-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.
Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach
Stewart‐Merrill, Suzanne B., Thompson, R. Houston, Boorjian, Stephen A. , Psutka, Sarah P. , Lohse, Christine M. , Cheville, John C. , Leibovich, Bradley C. , Frank, Igor, Psutka, Sarah P

Journal of Clinical Oncology | September 8, 2015 | Volume: 33 | Issue: 35 | Pages: 4151-4157

10.1200/jco.2015.61.8009 | PMID 26351352 Get It

Purpose The appropriate duration of surveillance for renal cell carcinoma (RCC) after radical or partial nephrectomy remains unknown, and evidence to support current guidelines are lacking. Herein, we provide an approach to surveillance that balances the risk of recurrence versus the risk of non-RCC death. Patients and Methods We identified 2,511 patients who underwent surgery for M0 RCC between 1990 and 2008. Patients were stratified for analysis by pathologic stage (pT1Nx-0, pT2Nx-0, pT3/4Nx-0, and pTanyN1), relapse location (abdomen, chest, bone, and other), age (< 50, 50 to 59, 60 to 69, 70-79 and ≥ 80 years), and Charlson comorbidity index (CCI; ≤ 1 and ≥ 2). Risks of disease recurrence and non-RCC death were estimated by using parametric models for time-to-failure with Weibull distributions. Surveillance duration was estimated at the point when the risk of non-RCC death exceeded the risk of recurrence. Results At a median follow-up of 9.0 years (interquartile range, 6.4 to 12.7 years), a total of 676 patients developed recurrence. By using a competing-risk model, vastly different surveillance durations were appreciated. Specifically, among patients with pT1Nx-0 disease and a CCI ≤ 1, risk of non-RCC death exceeded that of abdominal recurrence risk at 6 months in patients age 80 years and older but failed to do so for greater than 20 years in patients younger than age 50 years. For patients with pT1Nx-0 disease but a CCI ≥ 2, the risk of non-RCC death exceeded that of abdominal recurrence risk already at 30 days after surgery, regardless of patient age. Conclusion We present an individualized approach to RCC surveillance that bases the duration of follow-up on the interplay between competing risk factors of recurrence and non-RCC death. This strategy may improve the balance between the derived benefit from surveillance and medical resource allocation.